Skip to content

Effects of subanesthetic dose of esketamine on postoperative cognitive function and early recovery in elderly patients with hip fracture

Effects of subanesthetic dose of esketamine on postoperative cognitive function and early recovery in elderly patients with hip fracture

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104396
Enrollment
Unknown
Registered
2025-06-17
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction, POCD

Interventions

Esketamine group :Esketamine was administered intravenously at a dose of 0.2 mg/kg
Control group:Intraoperative normal saline infusion

Sponsors

People's Hospital of Fuyang City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1)Age >=65 years, no gender restriction; 2)ASA physical status classification: I-III; 3)Preoperative diagnosis of hip fracture, including intertrochanteric fracture, femoral trochanteric fracture, or femoral neck fracture; 4)Intact autonomous ability, clear consciousness, and ability to cooperate with the study protocol.Mini-Mental State Examination (MMSE) score >=23;Formal education duration >6 years.

Exclusion criteria

Exclusion criteria: 1)Patients with a history of psychiatric or neurological disorders, or those taking related medications; 2)Patients with a history of myocardial infarction or cerebrovascular accident; 3)Patients with severe respiratory or circulatory system diseases, or preoperative biochemical tests indicating renal dysfunction (serum creatinine >177 µmol/L) or active liver disease; 4)Patients who refused the study protocol or requested changes to the anesthesia method; 5)Patients lost to follow-up.

Design outcomes

Primary

MeasureTime frame
MMSE score;QoR-15 score;

Secondary

MeasureTime frame
RASS score;VAS score;Heart rate;Blood pressure;Oxygen saturation, SPO2;Length of PACU stay;Rescue analgesic use;Occurrence of adverse reactions during the use of analgesic pump;

Countries

China

Contacts

Public ContactYang Fangfang

People's Hospital of Fuyang City

Yangff0505@163.com+86 182 5536 3858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026